Inovio Clinical Trials Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 12-07-2024
- Paid Up Capital ₹ 0.10 M
as on 12-07-2024
- Company Age 5 Year, 7 Months
- Last Filing with ROC 31 Mar 2021
- Revenue 36.30%
(FY 2021)
- Ebitda
- Net Worth
- Total Assets 10.10%
(FY 2021)
About Inovio Clinical Trials
The Corporate was formerly known as Techzombie Solutions Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Soumendra Ray and Sivarajan Chettiar serve as directors at the Company.
- CIN/LLPIN
U74110UR2019PTC009813
- Company No.
009813
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 May 2019
- Date of AGM
22 Jun 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Udham Singh Nagar, Uttarakhand, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Inovio Clinical Trials?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Soumendra Ray  | Additional Director | 11-Apr-2022 | Current |
| Sivarajan Chettiar | Director | 25-Nov-2021 | Current |
Financial Performance of Inovio Clinical Trials.
Inovio Clinical Trials Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 36.3% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Inovio Clinical Trials?
In 2021, Inovio Clinical Trials had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Archeron Engineering & Consulting Private LimitedActive 14 years 8 monthsSoumendra Ray is a mutual person
- Reason Advisory & Industrial Solutions Private LimitedActive 2 years 10 months
Soumendra Ray is a mutual person
- Archeron Clinical Solutions Private LimitedActive 5 years 11 months
Soumendra Ray and Sivarajan Chettiar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Inovio Clinical Trials?
Unlock and access historical data on people associated with Inovio Clinical Trials, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Inovio Clinical Trials, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Inovio Clinical Trials's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
